Skip to main content

Table 4 Summary of studies using 3D strain in cancer patients who had received cardiotoxic drugs

From: A review of current trends in three-dimensional analysis of left ventricular myocardial strain

Author Year (Ref.#) Type of cancer n Treatment Echo timing Feasibility CTRCD
(%)
Pre-echo Post-echo Remarks
Mornos 2014 [71] various 79 Anthracycline (100%) Before and at 12 and 36 weeks 3D STE: 75% 14% 3D GLS: 19.4 ± 2.3%
3D GCS: 21.4 ± 1.7%
3D GRS: 42.4 ± 5.3%
17.5 ± 2.4%*
20.9 ± 1.7%
37.6 ± 5.4%*
Δ3D GLS was an independent predictor for future CTRCD. Δ3D GLS of 13.7% had an 88% sensitivity and a 71% specificity for CTRCD.
Tarr 2015 [39] various 25 Anthracycline (28%) Before and 3 months 2D STE: 100%
3D STE: 100%
NA 2D GLS: 15.0 ± 4.2%
2D GRS: 28.0 ± 10.6%
3D GLS: 13.0 ± 2.6%
3D GCS: 21.0 ± 4.5%
3D GRS: 28.0 ± 12.8%
14.0 ± 4.6%*
21.0 ± 11.5%*
12.0 ± 2.2%
22.0 ± 4.7%
26.0 ± 14.5%
3D global strains did not show a significant decrease after therapy.
Santoro 2017 [26] breast 100 Anthracycline (100%) Before and at 4 months 2D STE: 91% /90%
3D vol.: 88% /67%
3D STE: 84% /60%
NA 2D GLS: 22.2 ± 2.3%
3D LVEF: 62 ± 7%
3D GLS: 17.6 ± 3.2%
3D GCS: 16.8 ± 2.8%
3D GAS: 30.2 ± 4.5%
3D GRS: 47.4 ± 9.2%
20.1 ± 6.6%*
60 ± 7%*
16.2 ± 3.5%*
15.2 ± 2.9%*
27.5 ± 5.4%*
43.1 ± 10.7%
% reduction of 2D GLS > 15% was observed in 17 patients (17%).
3D-derived LVEF decreased < 50% in 4 out of 67 patients (6%).
Song 2017 [72] lymphoma 89 Anthracycline (100%) Before, at 3 weeks, and at the end of Tx. 2D STE: 93% /93%/93%
3D STE: 93% /93%/93%
NA 2D LVEF: 70 ± 3%
2D GLS: 21.5 ± 2.5%
3D GLS: 21.8 ± 2.9%
3D GCS: 29.9 ± 4.4%
69 ± 3%
20.7 ± 2.1%
27.5 ± 4.5%*
27.3 ± 5.0%*
2D GLS and LVEF did not change, but 3D GLS and 3D GCS were significantly reduced 3 weeks after therapy.
Zhang 2018 [73] breast 142 Anthracycline (100%)
Trastuzumab (9%)
Before and annually 3D STE: 94% NA 3D LVEF: 56.8%
3D GLS:16.8%
3D GCS: 27.3%
3D principal strain: 29.9%
51.5%*
15.3%*
24.2%*
26.0%*
3D LVEF, 3D GLS, 3D GCS, and 3D principal strain were associated with concurrent and subsequent changes in systolic function.
Chen 2019 [74] breast 83 Anthracycline (100%) Before, during, and after Tx. 3D STE:100% NA 3D GLS 18.1 ± 2.2%
3D GCS 18.7 ± 2.6%
3D GAS 34.1 ± 2.8%
3D GRS 44.9 ± 5.2%
14.9 ± 2.5%*
15.7 ± 0.3%*
23.9 ± 2.6%*
43.3 ± 4.9%
There was a significant correlation between 3D GAS and the culminating dose of anthracycline (r = 0.77).
Cruz 2019 [53] breast 105 Anthracycline (100%)
Trastuzumab (52%)
Before and during Tx. 2D STE: 100% (patients)/ 96% (segments)
3D STE: 100% (patients)/ 94% (segments)
23% 2D LVEF: 66 ± 8%
2D GLS: 21.1 ± 3.0%
3D LVEF: 62 ± 6%
3D GLS: 15.6 ± 3.4%
3D GCS: 14.0 ± 4.0%
3D GAS: 27.0 ± 8.5%
3D GRS: 42.0 ± 17.0%
58 ± 11%*
18.8 ± 3.1%*
54 ± 9%*
10.9 ± 4.1%*
11.0 ± 5.0%*
20.0 ± 9.0%*
28.5 ± 17.5%*
Percent reduction of 3D GCS (cut-off value of 34.2%) and that of 3D GRS (34.5%) predicted CTRCT with 70% diagnostic accuracy.
  1. CTRCD, cancer therapy related cardiac dysfunction; STE, speckle tracking echocardiography; Tx., therapy
  2. Other abbreviations are the same in Table 1
  3. *p < 0.05 versus baseline